Naar homepage     
Chronische Cerebro-Spinale Veneuze Insufficiëntie
Aanmelden op het CCSVI.nl forum 		Lees Voor (ReadSpeaker)    A-   A+
Over CCSVI.nl | Zoeken | Contact | Forum
CCSVI.nl is onderdeel van de
Franz Schelling Website
meer informatie
  
DISCLOSURES OF CANADIAN NEUROLOGISTS WITH THE PHARMACEUTICAL COMPANIES
Sunday, November 28, 2010 8:12 AM | Venöse Multiple Sklerose, CVI & SVI, CCSVI Volg link

Christopher Alkenbrack -

WILL ANGIOPLASTY FOR M.S. PATIENTS EVER GET A FAIR TRIAL ? http://www.facebook.com/topic.php?uid=110317832313822&topic=586

How can we trust the M.S. Society of Canada or their researchers to promote or investigate CCSVI if almost all of the major players have contracts with numerous pharmaceutical companies ?Below is a list of the professional disclosures from the ECTRIMS conference in Sweden in October of 2010. I`ve shortlisted the number of neurologists involved to those who currently serve on a committee with the MS Society of Canada, the committee of experts appointed by the Canadian Institutes of Health Research or who are participating either as lead investigator or secondary investigator in one of the CCSVI studies funded by the MS Society of Canada.CANADIAN MS NEUROLOGISTS DOING RESEARCH AND PRESENTING AT THE ECTRIMS CONFERENCE IN SWEDENLIST OF DISCLOSURES FROM THE ABSTRACTS OF THE ETRTIMS CONFERENCE ALL PAGE REFERENCES ARE TO THE FOLLOWING DOCUMENThttp://msj.sagepub.com/content/16/10_suppl/S7.citation...................................................................................................... 1. DR. V.W. YONG, Chair of the Canadian MS Society Medical Advisory Board, Member of the Canadian MS Society Biomedical Research Grants Review Committee, and Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in CanadaPAGE S310Disclosure: VW Yong has received honoraria from Teva Neuroscience and Bayer Healthcare Pharmaceuticals........................................................................................................ 2. DR. ANTHONY FEINSTEIN, Member of the Canadian MS Society Medical Advisory Board and the Clinical and Population Health Research Grants Review CommitteePAGE S11Disclosure: Dr. Feinstein has received honoraria from Merck Serono, Bayer HealthCare Pharmaceuticals and Teva Neuroscience........................................................................................................ 3. DR. MARK S. FREEDMAN,Member of the Canadian MS Society Medical Advisory Board, Participant Researcher of one of the studies funded by the MS Society of Canada in the $ 2.4 million.PAGE S23Disclosure: Dr Freedman has received grant support from Genzyme, and has acted as an advisor/consultant/steering committee member or speaker for Bayer, Biogen Idec, Teva, Merck Serono, Novartis and sanofi-aventis.PAGE S119Disclosure: M Freedman has received personal compensation for serving as a con- sultant for BioMS, Bayer, Novartis, Merck Serono and has received honoraria from Bayer, Pfizer, EMDSerono, Teva, Biogen Idec, and Genentech.PAGE S280Disclosure: M Freedman has received personal compensation for serving as a con- sultant for BioMS, Bayer, Novartis, Merck Serono and has received honoraria from Bayer, Pfizer, EMDSerono, Teva, Biogen Idec, and Genentech.PAGE S291Disclosure: Mark Freedman has received research support from Genzyme and has acted as advisor/consultant/steering committee member or speaker for Bayer, Biogen Idec, Teva, Merck Serono, Novartis, sanofi-aventis Hadj Benzerdjeb is an employee of sanofi-aventis.PAGE S348Disclosure: Dr Freedman has received grant support from Genzyme, and has acted as an advisor/consultant/steering committee member or speaker for Bayer, Biogen Idec, Teva, Merck Serono, Novartis and sanofi-aventis....................................................................................................... 4. DR. LUANE METZ, Member of the Multiple Sclerosis Society of Canada Medical Advisory Board and the Clinical and Population Health Research Grants Review CommitteePAGE: S152Disclosure: Dr. Metz has nothing to disclose with respect to this trial, but has received research funding from the MS Society of Canada, Neuroscience Canada, and the Network of Centres for Excellence (the Stem Cell Network) and from several philanthropists through the Hotchkiss Brain Institute, and has consulted to Teva Neuroscience, Biogen-Idec, EMD-Serono, Novartis, and Bayer.PAGE : S242Disclosure: O. Cedile, M. Løbne, H. Toft-Hansen and T. Owens have nothing to disclose........................................................................................................ 5. DR. JACK P. ANTEL, Member of the Canadian MS Medical Advisory Board, and Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in CanadaPAGE: S157Disclosure: G. John, A. Bar-Or and J. Antel are recipients of a research grant from Teva Pharmaceuticals....................................................................................................... 6. DR. PAUL O’CONNOR, Member of the Canadian MS Medical Advisory Board, Member of the Canadian MS Society Biomedical Research Grants Review Committee, and Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in CanadaPAGE: S23Disclosure: Paul O’Connor has received consulting fees and/or research support for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci, Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche, sanofi-aventis, Teva and Warburg Pincus.PAGE: S34Disclosure: Dr O’Connor has received support in the form of consultation fees or study grant support from the following companies: Bayer, Biogen Idec, EMD Serono, Novartis, Sanofi Aventis, Actelion, Eli Lilly, Genentech, Roche, and Warburg Pincus.PAGE: S120P O’Connor has received personal compensation for consulting from Biogen Idec, Bayer, Genentech, Roche, Teva, sanofi avventis, and Novartis. He has received grant support from Bayer, Genentech, sanofi aventis, BioMS, and Novartis.PAGE: S142Paul O’Connor has received consulting fees and/or research support for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci, Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche, sanofi-aventis, Teva and Warburg Pincus.PAGE: S143Disclosure: P O’Connor has received consulting fees from Biogen Idec, Sanofi- Aventis, Novartis, EMD Serono, Bayer, Teva Neuroscience and Genentech.PAGE: S147Disclosure: Paul O’Connor Consulting fees from Biogen Idec, Sanofi Aventis, Novartis, EMD Serono, Bayer, Teva Neuroscience, GenentechPAGE: S159Disclosure: P O’Connor has received compensation for consulting from Biogen Idec, Bayer, Genentech, Roche, Teva, sanofi-aventis, Novartis; and grant support from Bayer, Genentech, sanofi-aventis, BioMS, and Novartis.PAGE: S170Disclosure: P O’Connor has received consultancy and research grant support from Bayer, Biogen-Idec, EMD Serono, Teva, Genentech, Roche, Sanofi- Aventis and Novartis.PAGE: S290Disclosure: Paul O’Connor Consulting fees from Biogen Idec, Sanofi Aventis, Novartis, EMD Serono, Bayer, Teva Neuroscience, GenentechPAGE: S291Disclosure: Paul O’Connor has received consulting fees and/or research support for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci, Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche, sanofi-aventis, Teva and Warburg Pincus.PAGE: S295Disclosure: Paul O’Connor Consulting fees from Biogen Idec, Sanofi Aventis, Novartis, EMD Serono, Bayer, Teva Neuroscience, GenentechPAGE: S348Disclosure: Paul O’Connor has received consulting fees and/or research support for MS trials from Actelion, Bayer, Biogen Idec, BioMS, Cognosci, Daiichi Sankyo, EMD Serono, Genentech, Genmab, Novartis, Roche, sanofi-aventis, Teva and Warburg Pincus....................................................................................................... 7. DR. JODIE BURTON, Member of the Biomedical Research Grants Review Committee, MS Society of CanadaPAGE: S152Disclosure: Dr. Burton has nothing to disclose with respect to this trial, but has but has received research support from Direct-MS, unrestricted travel and educational support from TEVA Neuroscience Canada, Biogen Idec Canada and EMD Serono and has served on advisory boards for Biogen Idec Canada...................................................................................................... 8. The name of this neurologist was removed as this person had no disclosures...................................................................................................... 9. DR. ANTHONY TRABOULSEE, Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in Canada, , Recipient and Principal Researcher of one of the studies funded by the MS Society of Canada in the $ 2.4 million.PAGE: S111Disclosure: Anthony Traboulsee received honoraria for data safety monitoring committee participation from Merck Serono and Daiichi, honoraria for lectures from Bayer, Merck Serono, Teva Neurosciences and receives research support from the Canadian Institutes for Health Research and the Multiple Sclerosis Society of Canada.PAGE: S142Disclosure: Anthony Traboulsee has received personal compensation from: Merck Serono for data safety monitoring board (DSMB) membership and for co-chairing a symposium; Bayer Health Care for speaking; TevaNeurosciences for chairing a symposium; Neura as a member of an editorial advisory board; Daiichi for DSMB membership.PAGE: S261Disclosure: Anthony Traboulsee received honoraria for data safety monitoring committee participation from Merck Serono and Daiichi, honoraria for lectures from Bayer, Merck Serono, Teva Neurosciences and receives research support from the Canadian Institutes for Health Research and the Multiple Sclerosis Society of Canada.......................................................................................................... 10. DR. AARON MILLER, Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in CanadaPAGE: S23Disclosure: Dr Miller has received research support from Acorda Therapeutics, BiogenIdec, Genentech, Genzyme, Sanofi-aventis, and Teva Neuroscience; has served as a consultant to Acorda Therapeutics, BiogenIdec, BioMarin, Daiichi-Sankyo, EMD Serono, Glaxo Smith Kline, Merck Serono, Novartis, ONO, and Teva Neuroscience; and on the speakers bureau for Acorda Therapeutics, Biogen Idec, EMD Serono, Pfizer, and Teva Neuroscience.PAGE: S348Disclosure: Dr Miller has received research support from Acorda Therapeutics, BiogenIdec, Genentech, Genzyme, Sanofi-aventis, and Teva Neuroscience; has served as a consultant to Acorda Therapeutics, BiogenIdec, BioMarin, Daiichi-Sankyo, EMD Serono, Glaxo Smith Kline, Merck Serono, Novartis, ONO, and Teva Neuroscience; and on the speakers bureau for Acorda Therapeutics, Biogen Idec, EMD Serono, Pfizer, and Teva Neuroscience...................................................................................................... 11. DR. DOUGLAS ARNOLD, Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in Canada, Participant Researcher of one of the studies funded by the MS Society of Canada in the $ 2.4 million.PAGE: S58Disclosure: Dr. D.L. Arnold has received honoraria from serving on the scientific advisory boards of Biogen Idec and Genentech; holds a patent (Method of Evaluating the Efficacy of Drug on Brain Nerve Cells); has received speaking fees from Biogen Idec, Genentech, the MS Forum, and the University of South Florida College of Medicine; has served as a paid consultant for Biogen Idec, Eisai Medical Research Inc., Genentech, MS Forum, NeuroRx Research, Novartis, and Teva Neuroscience; and has received research support from Biogen Idec, the Canadian Institutes of Health ResearchPAGE: S107Disclosure: Douglas Arnold is the holder of research grants from the CIHR and the MSSC.PAGE: S110Disclosure: Douglas Arnold is the holder of research grants from the CIHR and the MSSC and thanks Biogen Idec and Genentech for allowing us access to their clinical trial data.PAGE: S159Disclosure: D Arnold has received compensation and/or support for research activities from Bayer-Schering, Biogen Idec, Genentech, NeuroRx Research, Roche, and Teva Neuroscience.PAGE: S201Disclosure: DL Arnold has received honoraria from serving on the scientific advi- sory boards of Biogen Idec and Genentech; holds a patent (Method of Evaluating the Efficacy of Drug on Brain Nerve Cells); has received speaking fees from Biogen Idec, Genentech, the MS Forum, and the University of South Florida College of Medicine; has served as a paid consultant for Biogen Idec, Eisai Medical Research Inc., Genentech, MS Forum, NeuroRx Research, Novartis, and Teva Neuroscience; and has received research support from Biogen Idec, the Canadian Institutes of Health Research (PI: Grant MOP84367; Coinvestigator: Grant MOP 15630), and the Multiple Sclerosis Society of Canada..................................................................................................... 12. DR. BRENDA BANWELL, Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in Canada, Recipient and Principal Researcher of one of the studies funded by the MS Society of Canada in the $ 2.4 million.PAGE: S19Disclosure: B Banwell has received speaker’s honoraria from Merk-Serono, Teva Neuroscience, and Biogen-IDEC.PAGE: S58Disclosure: Dr. B. Banwell has received speaker’s honoraria from Merk-Serono, Teva Neuroscience, and Biogen-IDEC. Dr. B Banwell serves as an Editor for Multiple Sclerosis, for which she received no remuneration.PAGE: S201Disclosure: B Banwell has received speaker’s honoraria from Merk-Serono, Teva Neuroscience, and Biogen-IDEC. Dr. B Banwell serves as an Editor for Multiple Sclerosis, for which she received no remuneration.PAGE: S216Disclosure: Dr. B. Banwell has received speaker’s honoraria from Merk-Serono, Teva Neuroscience, and Biogen-IDEC. Dr. B Banwell serves as an Editor for Multiple Sclerosis, for which she received no remuneration......................................................................................................... 13. DR. JERRY WOLINSKY, Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in CanadaPAGE: S23Disclosure: Over the last 12 months, Dr. Wolinsky has served on advisory boards or data monitoring committees, has consulting agreements, or received speaker honoraria from Acorda Therapeutics, Bayer HealthCare, Consortium of MS Clinics, Eli Lilly, EMD Serono, Facet Biotech, Johns Hopkins University, Medscape CME, Novartis, Peptimmune, sanofi-aventis, Serono Symposia International Foundation, Teva and Teva Neurosciences, the National Multiple Sclerosis Society, Northwestern University, the University of Buffalo, the University of South Florida Professionals Conferencing and UCB; royalties for outlicensed monoclonal antibodies through the UTHSCH to Millipore (Chemicon International) Corporation since 1993; and receives research or contractual support from the Clayton Foundation for Research, the NIH [2 U01 NS045719-06 (PI of the subcontract to UTHSCH for image analysis), 2RO1-EB002095-06A1 (Co-I)], and sanofi-aventis; he was compensated for his efforts as an Associate Editor for ACP Medicine, BC Decker.PAGE: S159Disclosure: J Wolinsky has received compensation from Antisense Therapeutics, Ltd., Genentech, Inc., EMD Serono, Novartis, sanofi-aventis, Teva Pharmaceuticals, Teva Neurosciences, and UCB for consulting ser- vices. Dr. Wolinsky has received compensation from BCDecker for serving as an Associate Editor of ACP Medicine. He has also received royalty payments from Chemicon for licensed technology and finan- cial support for research activities from sanofi-aventis and the National Institutes of Health.PAGE: S306Disclosure: .Wolinsky has received compensation from Novartis as an advisor......................................................................................................... 14. DR. RUTH ANN MARIE, Member of the Expert Committee to the Canadian Institute of Health Research that refused to fund clinical trials in Canada, Participant Researcher of one of the studies funded by the MS Society of Canada in the $ 2.4 million.PAGE: S334Disclosure: Ruth Ann Marrie has consulted for Berlex, BioMS, EMD Serono and Sanofi Aventis.PAGE: S335Disclosure: Ruth Ann Marrie has consulted for Berlex, BioMS, EMD Serono and Sanofi Aventis.......................................................................................................... 15. DR. AMIT BAR OR, Participant Researcher of one of the studies funded by the MS Society of Canada in the $ 2.4 million.PAGE: S291Disclosure: Amit Bar-Or has received research support from Biogen-Idec, Genentech and Teva Neuroscience, and received fees for consulting, serving on scientific advisory boards and/or speaking activities from Bayer, Bayhill Therapeutics, Berlex, Biogen-Idec, BioMS, Diogenix, Eli- Lilly, Genentech, GSK, Guthy-Jackson/GGF, Merck-Serono, Novartis, Ono Pharmacia, Roche, sanofi-aventis, Teva Neuroscience andWyeth.

?